霍奇金与非霍奇金淋巴瘤中的检查点阻断治疗
经典霍奇金淋巴瘤(cHL)因9p24.1基因改变导致PD-1配体组成性表达,对PD-1阻断高度敏感,复发/难治性疾病缓解率约70%。非霍奇金淋巴瘤(NHL)多数对PD-1单药敏感性低,但原发纵隔B细胞淋巴瘤、原发中枢神经系统淋巴瘤、原发睾丸淋巴瘤及EBV感染淋巴瘤可能对检查点阻断敏感。本综述描述cHL与NHL检查点阻断的生物学基础并总结迄今临床数据。
要点
- cHL因9p24.1改变高表达PD-1配体,复发/难治患者对PD-1阻断缓解率约70%。
- 多数NHL对PD-1单药敏感性低,NHL研究转向其他检查点或PD-1联合治疗。
- 原发纵隔B细胞淋巴瘤、原发中枢神经系统淋巴瘤、原发睾丸淋巴瘤及EBV感染淋巴瘤可能对PD-1阻断敏感。
核心结论
- cHL对PD-1阻断高度敏感,复发/难治性疾病缓解率约70%;多数NHL对PD-1单药敏感性低,但部分亚型可能敏感。
研究设计与样本
- 综述,描述cHL与NHL检查点阻断的生物学基础并总结迄今临床数据。
主要发现
- cHL中9p24.1基因改变近乎普遍,导致PD-1配体组成性表达,复发/难治性疾病对PD-1阻断缓解率约70%。
- NHL一般不频繁出现9p24.1改变,不共享cHL对PD-1阻断的易感性。
- 原发纵隔B细胞淋巴瘤、原发中枢神经系统淋巴瘤和原发睾丸淋巴瘤频繁存在9p24.1改变,EBV感染淋巴瘤中EBV感染导致PD-L1表达增加。
关键数值与推荐
- cHL复发/难治性疾病对PD-1阻断的缓解率约70%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Classical Hodgkin lymphoma (cHL) is characterized by nearly universal genetic alterations in 9p24.1, resulting in constitutive expression of PD-1 ligands. This likely underlies the unique sensitivity of cHL to PD-1 blockade, with response rates of ∼70% in relapsed/refractory disease. There are now numerous clinical trials testing PD-1 inhibitors in earlier stages of treatment and in combination with many other therapies. In general, non-Hodgkin lymphomas (NHLs) do not display a high frequency of 9p24.1 alterations and do not share cHL's vulnerability to PD-1 blockade. However, a few entities have genetic or immunologic features that may predict sensitivity to immune checkpoint blockade. These include primary mediastinal B cell lymphoma, primary central nervous system lymphoma, and primary testicular lymphoma, which harbor frequent alterations in 9p24.1, as well as Epstein Barr virus (EBV)-infected lymphomas, where EBV infection leads to increased PD-L1 expression. Although these subtypes may be specifically vulnerable to PD-1 blockade, the majority of NHLs appear to be minimally sensitive to PD-1 blockade monotherapy. Current investigations in NHL are therefore focusing on targeting other checkpoints or studying PD-1-based combination therapy. Looking forward, additional insight into the most common mechanisms of resistance to immune checkpoint inhibitors will be important to guide rational clinical trial design. In this review, we describe the biological basis for checkpoint blockade in cHL and NHL and summarize the clinical data generated to date. Guided by our rapidly evolving understanding of the pathobiology of various lymphoma subtypes, we are hopeful that the role of checkpoint inhibitors in lymphoma treatment will continue to grow.
引用
- Merryman RW, Armand P, Wright KT, et al. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017. PMID: 29296917. doi:10.1182/bloodadvances.2017012534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。